10 Top Insider Stock Buys And Sells In January

6. Ionis Pharmaceuticals, Inc (NASDAQ:IONS)

Number of insiders selling: 10

Market Cap: $4.9 billion

Sixth on our list of 10 Top Insider Stock Buys And Sells in January is a biotechnology company, Ionis Pharmaceuticals. The Carlsbad, California-headquartered company is engaged in the discovery and development of RNA-targeted therapeutics. At the moment, Ionis has six marketed medicines and a pipeline of innovative therapies for rare illnesses, and neurology and cardiology treatments.

In December, the U.S. Food and Drug Administration (FDA) authorized Tryngolza, an Ionis’ RNA-targeted therapy for the treatment of familial chylomicronemia syndrome (FCS). Tryngolza is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and offers a clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day).

Last month, 10 insiders, sold a total of around $5.21 million worth of Ionis shares at an average price of $32.63 per share. Out of the total amount, the company’s CEO, P Brett Monia, sold 46,687 shares, worth $1.52 million, reducing his holdings to 219,526 Ionis shares. Monia also sold 38,843 shares in February.

The stock is now trading at $31.04 per share, having lost 11.21% since the beginning of the year. Over the last 12 months, Ionis shares dropped 30.01%. With 10 sales in January, and a market capitalization of $4.9 billion, Ionis Pharmaceuticals is also one of 10 Mid-Cap Stocks Insiders Are Selling Recently.

The average rating on Ionis stock from 18 analysts is “Buy,” with a price target of $62, which is an increase of 99.74% from the latest price, writes StockAnalysis.